General description

A furanyl thiazolidinone compound that binds CD11b αA/αI domain in a reversible manner and stabilizes αA in a high-affinity binding conformation toward known CD11b/CD18 (αMβ2; CR3; Mac-1) ligands, fibrinogen, ICAM-1, and iC3B. Reported to be superior to IMB-10 (Cat. No. 407271) in enhancing Mac-1-mediated cell adhesion (EC₅₀ = 4 vs. >50 µM on fibrinogen surface). Effectively suppresses leukocyte recruitment in various inflammatory disease models involving mice, rats, and zebrafish embryos in vivo.

A furanyl thiazolidinone compound that binds CD11b αA/αI domain in a reversible manner and stabilizes αA in a high-affinity binding conformation toward known CD11b/CD18 (αMβ2; CR3; Mac-1) ligands, fibrinogen, ICAM-1, and iC3B. Reported to be superior to IMB-10 (Cat. No. 407271) in enhancing Mac-1-mediated cell adhesion (EC₅₀ = 4 vs. >50 µM on fibrinogen surface). Effectively suppresses leukocyte recruitment in various inflammatory disease models in vivo, including thioglycolate-induced peritonitis (10 nmol/0.2 ml/mouse; i.v.), anti-GBM-induced nephritis (25 nmol/0.5 ml/mouse; i.p.), balloon-induced artery injury (50 nmol/1 ml/rat; i.m.), and zebrafish tailfin injury.CR3

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Maiguel, D., et al. 2011. Sci. Signal.4, ra57.

Packaging

25 mg in Glass bottle

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)